安体舒通减轻博莱霉素A5引起的大鼠肺纤维化

目的探讨醛固酮在肺纤维化发病中的意义及拮抗醛固酮治疗肺纤维化的可行性。方法实验分三组：正常对照组（６只）、纤维化组（２５只）及治疗组（１１只）。纤维化组用博莱霉素Ａ５制作大鼠肺纤维化模型，治疗组饮水中每日给予安体舒通１００ｍｇ／ｋｇ，２８天后观察血浆、肺泡灌洗液（ＢＡＬＦ）及肺组织的醛固酮及肺组织胶原含量。结果纤维化组大鼠血浆醛固酮有升高趋势，但未达显著性（纤维化组４６９±１６１ｐｇ／ｍｌｖｓ，对照组３１９±１１５ｐｇ／ｍｌ，Ｐ＞０．０５）；安体舒通可减轻肺纤维化程度，肺胶原含量较纤维化组少２５％（治疗组３．４±０．５ｍｇ／ｇｌｕｎｇｖｓ，纤维化组４．６±１．２ｍｇ／ｇｌｕｎｇ，ｑ＝３．７８９３，Ｐ＜０．０５）。治疗组肺组织蛋白含量较纤维化组少２２％（治疗组５０±４ｍｇ／ｇｌｕｎｇｖｓ，纤维化组６５±６ｍｇ／ｇｌｕｎｇ，Ｐ＜０．０１）。结论安体舒通对肺纤维化有一定的保护作用，醛固酮可能参与肺纤维化的发病过程。

Spironolactone ameliorates rat pulmonary fibrosis induced by bleomycin A 5

OBJECTIVE: The purpose of this study was to investigate the role of aldosterone in pulmonary fibrosis and the protective effect of anti-aldosterone treatment. METHOD: Rats were divided into control, fibrosis and treatment groups; rat pulmonary fibrosis was induced by endotracheal injection of bleomycin A5 and spironolactone was given 100 mg/kg daily in drinking water to treatment group. 28 days later, plasma, bronchoalveolar lavage fluid(BALF) and tissue aldosterone concentration, as well as lung collagen levels, were determined. RESULT: Plasma aldosterone was higher in fibrosis group than that in control group(469 +/- 161 pg/ml and 319 +/- 115 pg/ml, respectively), but without significant difference (P > 0.05); spironolactone could ameliorate the extent of pulmonary fibrosis, the level of lung collagen was 25% less than that of fibrosis group (3.4 +/- 0.5 mg/g lung and 4.6 +/- 1.2 mg/g lung, respectively; q = 3.7893, P < 0.05), and the level of lung protein was 22% less (50 +/- 4 mg/g lung and 65 +/- 6 mg/g lung, respectively; P < 0.01). CONCLUSION: Spironolactone had some protective effects on pulmonary fibrosis, and aldosterone might play a role in the development of pulmonary fibrosis.